Tosoh Bioscience Completes the Acquisition of Semba Biosciences
Tosoh Bioscience LLC, has announced that it has completed the acquisition of Semba Biosciences, a privately held Wisconsin company. Semba Biosciences is a leading innovator in the field of multi-column chromatography (MCC) instrumentation and technology for downstream purification of biologics.
Ali Soleymannezhad, VP global marketing and business development of Tosoh Bioscience LLC said, “We are thrilled to welcome the Semba Biosciences team to the Tosoh family. For long we have admired Semba’s technology and innovation, pioneering the Simulated Moving Bed (SMB) technology in the biopurification processes. Since our first equity investment back in 2018, the company has successfully hit every product development milestone set by Tosoh Bioscience and will soon be ready to launch the Octave® BIO System, a state-of-the-art benchtop MCC unit for bioprocess development, and ProGMP™, the most efficient MCC skid designed for larger-scale biological manufacturing. This marks a new era for Tosoh Bioscience and confirms our commitment to provide our customers with the latest solutions and technologies.”
“We are extremely pleased and excited to become part of the Tosoh Bioscience worldwide organization,” said Robert Mierendorf, Ph.D., president and CEO of Semba Biosciences. “By combining Semba Biosciences’ advanced Simulated Moving Bed (SMB) technology with Tosoh Bioscience’s best-in-class resins, we will be able to offer unparalleled efficiency and productivity in downstream processes and significantly decrease the cost of manufacturing.”
Tosoh Bioscience LLC is planning on expanding the current Semba team in Madison, WI, creating a global center of excellence for continuous chromatography.